Archer Aviation reports manufacturing ramp with six aircraft in production
BOSTON & MONTREAL - enGene Holdings Inc. (NASDAQ:ENGN), a biotech firm specializing in non-viral genetic medicines, announced the resignation of Chief Medical Officer Dr. Raj Pruthi, effective June 16, 2025. Dr. Pruthi will assist in the transition of his duties to the company’s team of urology and clinical experts.
The company expressed gratitude towards Dr. Pruthi for his contributions and dedication during his tenure and extended best wishes for his future endeavors. The transition plan aims to ensure continuity in enGene’s strategic and operational activities without disruption.
enGene is currently focused on advancing its lead program, detalimogene voraplasmid, designed to treat Non-Muscle Invasive Bladder Cancer (NMIBC). This therapeutic candidate is being evaluated in the LEGEND Phase 2 study, which includes a pivotal cohort for BCG-unresponsive patients with carcinoma in situ (CIS). The study leverages enGene’s proprietary DDX platform, which facilitates the delivery of genetic medicines to mucosal tissues. Trading at $4.20, InvestingPro analysis indicates the stock is currently undervalued, with analyst price targets ranging from $7 to $34.
The company’s forward-looking statements, as customary, are subject to various factors, risks, and uncertainties that could affect their outcomes. These include challenges in recruiting and retaining qualified personnel, establishing clinical trial sites, patient enrollment, executing clinical development plans, and obtaining regulatory approvals within anticipated timelines. With the next earnings report due on June 13, 2025, InvestingPro subscribers can access detailed financial metrics, including the company’s strong liquidity position with a current ratio of 17.16 and minimal debt-to-equity ratio of 0.1.
enGene’s future plans and prospects are detailed in filings with Canadian securities regulators on SEDAR+ and the U.S. Securities and Exchange Commission (SEC) on EDGAR. The company has emphasized that while it may update forward-looking statements in the future, it is under no obligation to do so.
This announcement is based on a press release statement from enGene Holdings Inc. and is intended to provide information on the company’s recent management change and ongoing clinical programs.
In other recent news, enGene Holdings Inc. has appointed Amy Pott as its new Chief Global Commercialization Officer. This strategic move comes as the company prepares for the anticipated launch of its lead investigational agent, detalimogene voraplasmid, aimed at treating non-muscle invasive bladder cancer (NMIBC). The investigational medicine is currently in the LEGEND Phase 2 study, and enGene plans to submit a Biologics License Application (BLA) to the FDA in mid-2026. Analysts from Citizens JMP have maintained a Market Outperform rating for enGene with an $18.00 price target, highlighting the company’s potential in the evolving NMIBC treatment landscape. Meanwhile, H.C. Wainwright reiterated a Buy rating with a $25.00 price target, citing promising early results from the LEGEND study. Detalimogene voraplasmid has shown a 71% complete response rate at any time and a 47% rate at six months, which is favorable compared to other recent drug approvals. The FDA has also granted Fast Track designation to detalimogene voraplasmid, recognizing its potential to address unmet medical needs. Investors are closely monitoring enGene’s progress, especially with anticipated updates from the pivotal LEGEND cohort expected in the latter half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.